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Endoscopic resection has been accepted as an alternative to gastrectomy for early gastric cancer (EGC), providing comparable survival rates and a better quality of life. 1 Preserving most of the non-cancerous mucosa, however, resulted in the development of metachronous gastric cancer (MGC) in >20% of the patients during the 10 years after endoscopic resection. 1 Helicobacter pylori eradication is recommended by various guidelines and consensus reports after endoscopic resection of EGCs. Indeed, it is the only available intervention that can possibly reduce the risk for MGCs. However, the results from randomized controlled trials regarding whether the eradication of H. pylori can reduce the development of MGCs are still conflicting.
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Furthermore, there is little information on the effect of H. pylori eradication on premalignant conditions, such as gastric mucosal atrophy and intestinal metaplasia, in a group of people with a high risk of gastric cancer. In this issue of Gut and Liver, Han et al. 4 retrospectively followed 565 patients who had undergone endoscopic resection of EGC between 2005 and 2011 for a median of 60 months. The patients were divided into the H. pylori-negative (n=157), -eradicated (n=212), and -persistent (n=196) groups and then followed for the changes in atrophic gastritis and intestinal metaplasia and the development of MGCs. Histologic grades of corpus atrophy were similar between the H. pylori-eradicated and -persistent groups at baseline (1.06 and 1.15, respectively, p>0.05), but corpus atrophy was significantly less severe in the eradicated group than in the persistent group at follow-up (1.03 and 1.29, respectively, p=0.029). The H. pylori negative group showed a constantly less severe corpus atrophy at baseline and follow-up than both the H. pylori-eradicated and -persistent groups (all p<0.05). There were no noticeable differences or changes in the antrum atrophy or intestinal metaplasia. The following interpretations can be made. First, H. pylori eradication could delay the progression of corpus atrophy even in patients who have already developed gastric cancer but not the progression of antral atrophy or intestinal metaplasia. Gastric atrophy and intestinal metaplasia may not be reversed in these patients, unlike that suggested by the results from the previous studies in cancer-naïve people. 5 Second, H. pylori eradication may reduce the risk of developing MGCs, and the effect would be more prominent in patients younger than 70 years. These results augment the current evidence favoring H. pylori eradication after endoscopic resection of EGC. Therefore, H. pylori eradication would be the most beneficial among the patients with EGC who are younger than 70 years and with no or low grades of corpus atrophy because it could not reverse atrophy but only slows the progression. The authors suggested delayed progression of corpus atrophy as a possible link between H. pylori eradication and the reduced incidence of MGCs. However, it was not shown whether the corpus atrophy was associated with the development of MGCs in the analysis. Actually, only age, not atrophy or H. pylori infection, was independent risk factor for developing MGC in the adjusted analysis. Moreover, although H. pylori eradication was associated with lower grades of corpus atrophy, it was not associated with the grades of intestinal metaplasia. How did the progression of corpus atrophy affect the development of MGC without considerable progression of metaplasia? First, it is possible that the histologic grade of intestinal metaplasia was not a proper measure to reflect the changes posed by H. pylori eradication. It was suggested that the distribution of intestinal metaplasia could be a reliable predictor for the risk of gastric cancer. 6 Second, gastric atrophy may play a crucial role in the gastric carcinogenesis, whereas intestinal metaplasia might be a mere bystander. Theories were suggested that mucosal atrophy may offer the homing to cancer stem cells in H. pylori-associated gastric cancer. 7 Third, it is also possible that delayed progression of atrophy may not be related to the decreased risk for MGCs after H. pylori eradication. The two findings could only have coincided and another mechanism, such as promoter methylation of tumor suppressor genes, could have played a role in metachronous recurrence. 8 It is also noticeable that the H. pylori-negative group showed the highest incidence of MGC despite the lowest grades of corpus atrophy, which also raises questions about the association between corpus atrophy and the risk for MGC. Another retrospective cohort study showed a lower risk for MGC among H. pylori-negative patients with EGC. 9 Heterogeneity in the definitions of H. pylori negativity and false negativity among the tests for H. pylori infection might be the reason for these conflicting results. Thus, caution is necessary during the interpretation of the results in the H. pylori-negative group. In summary, this study suggests that H. pylori eradication may reduce the progression of corpus atrophy and the development of MGC, especially in patients younger than 70 years. This study is significant because the authors systematically and histologically evaluated the changes in precancerous lesions after H. pylori eradication in patients who underwent endoscopic resection of EGC. The observation that the progression of corpus atrophy is delayed by H. pylori eradication warrants further studies that will explore the link between H. pylori eradication and the development of MGC.
